I am a
Home I AM A Search Login

Papers of the Week

Papers: 27 Jan 2024 - 2 Feb 2024

2024 Jan 24

Lancet Neurol


Safety and efficacy of laquinimod for Huntington’s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.


Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF


Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington’s disease. Studies with laquinimod in transgenic rodent models of Huntington’s disease suggested improvements in motor function, reduction of brain volume loss, and prolonged survival. We aimed to evaluate the safety and efficacy of laquinimod in improving motor function and reducing caudate volume loss in patients with Huntington’s disease.